



ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to the ShareSoc Members Network (<http://sharesoc.ning.com>) in a Forum entitled "ShareSoc Growth Company Seminar Reports" soon after the Seminar. Use the site search facility at top right to locate those for a particular company if you cannot find the Forum.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Bioventix

BVXP 2975p ▼ **-75.0** **-2.5%**Adventurous, Small Cap, **High Flyer**

Market Cap

£156.8m

Quality

92

Enterprise Value

£149.8m

Value

13

Revenue

£8.75m

Momentum

90

Market Cap Rank

901st / 1923

StockRank™**76**Zoom 1m 3m 6m YTD **1y** 2y 3y 5y All**Momentum**

Relative Strength (%)

1m -6.6% ●

3m +4.4% ●

1yr +14.5% ●

Volume Change (%)

10d v 3m +68.3% ●

Price vs... (%)

52w High -8.8% ●

50d MA -3.85% ●

200d MA +11.6% ●

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (ttm) 28.2

PEG Ratio (ttm) n/a

EPS Growth (ttm) -1.00 %

Dividend Yield (ttm) n/a %

Valuation (ttm)

Price to Book Value 14.2

Price to Tang. Book 14.2

Price to Free Cashflow 27.0

Price to Sales 17.9

EV to EBITDA 21.5

Quality

vs. industry vs. market

Return on Capital 61.9 %

Return on Equity 53.5 %

Operating Margin 78.1 %

Health Trend

Piotroski F-Score

7

**Bankruptcy Risk**

Altman Z2-Score

202.8

**Earnings Manipulation Risk****High****Magic Formula Score**

737 80% B+

**Other Ratios**

Leverage (ttm)	total	-intang	+pension
Gross Gearing	%		
Net Gearing	%	-63.5	-63.5
Cash / Assets	%	58.8	58.8

Liquidity (ttm)	Efficiency (ttm)
Curr. Ratio	13.2 ● Asset Turnover 0.79
Quick Ratio	12.9 ● Rec's Turnover 4.10
Interest Cov.	100.0 ● Stock Turnover 2.25

Recent History

vs. industry vs. market

Latest interim period (ended 30th Jun '18) vs. prior year

Sales Growth 7.75 %

EPS Growth -23.6 %

3yr Compound Annual Growth Rate

Sales Growth 26.4 %

EPS Growth 21.9 %

DPS Growth -100.0 %

Margin of Safety (beta)

Broker Target	-13%
Relative to Sector	-62%
Graham Formula	-20%
Stability Value (EPV)	-73%

Screens Passed 1


BVXP qualifies for **Beneish M-Score Screen (in Short Selling)**.

[View Screen](#) · [View Checklist](#)

Financial Summary


Balance Sheet · Income Statement · Cashflow

Year End 30th Jun		2013	2014	2015	2016	2017	2018	2019E	2020E	CAGR / Avg
Revenue	£m	2.71	3.54	4.33	5.52	7.25	8.75	8.00	6.60	+26.5%
Operating Profit	£m	1.81	2.20	3.10	4.21	5.72	6.83			+30.4%
Net Profit	£m	1.52	1.82	2.56	3.49	4.92	5.66	5.00		+30.1%
EPS Reported	p	30.3	36.1	49.8	68.0	94.7	108.3			+29.0%
EPS Normalised	p	40.5	49.9	59.7	81.8	109.4	108.3	100.1		+21.7%
EPS Growth	%	+19.7	+23.1	+19.7	+37.0	+33.7	-1.0	-7.58		
PE Ratio	x					28.2	30.5	n/a		
PEG	x					n/a	n/a	n/a		
Profitability										
Operating Margin	%	66.9	62.3	71.5	76.2	78.9	78.1			+72.3%
ROA	%		35.3	40.4	44.6	51.4	50.9			
ROCE	%	43.0	42.1	46.9	51.1	56.3	61.9			+50.2%
ROE	%		38.5	43.3	47.2	53.6	53.5			+47.2%
Cashflow										
Op. Cashflow ps	p	26.7	35.1	41.8	62.7	74.8	113.3			+33.5%
Capex ps	p	0.42	0.038	2.21	0.41	0.42	2.06			+37.1%
Free Cashflow ps	p	26.3	35.0	39.5	62.3	74.4	111.2			+33.5%
Dividends										
Last ex-div: 25th Oct, paid: 9th Nov more...										
Dividend ps	p	14.6	24.0	32.6	42.5	51.0		73.0		-100.0%
Dividend Growth	%	+20.4	+64.7	+35.8	+30.4	+20.0				
Dividend Yield	%							2.39		
Dividend Cover	x	2.08	1.50	1.53	1.60	1.86		1.37		
Balance Sheet										
Cash etc	£m	2.59	3.35	4.13	5.38	6.17	6.99			+22.0%
Working Capital	£m	3.76	4.82	6.12	7.71	9.52	10.2			+22.2%
Net Fixed Assets	£m	0.44	0.42	0.49	0.51	0.64	0.79			+12.5%
Net Debt	£m	-2.59	-3.35	-4.13	-5.38	-6.17	-6.99			
Book Value	£m	4.20	5.24	6.58	8.21	10.1	11.0			+21.2%
Average Shares	m	5.03	5.03	5.14	5.14	5.20	5.23			+0.8%
Book Value ps	p	83.7	103.8	130.4	162.5	197.4	214.3			+20.7%

Graphical History Current Fiscal Year 2019

Broker Forecasts				30th Jun 2019			30th Jun 2020		
Price Target: 26.5 (-13.11% below Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				5.00m	100.1	73.0	-	-	87.0
1m Change				-	-	-	-	-	-
3m Change				-	+1.59	-	-	-	-

Broker Consensus Trend



Profile Summary



Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.

Directors: [P. Harrison](#) (CEO), [Ian Nicholson](#) (NEC) 54, [Kim Tan](#) (DRC) 55, [T. Turner](#) (DRC), [Nick McCooke](#) (NED),

No. of Employees: 16

No. of Shareholders: n/a

Last Annual	June 30th, 2018	Sector	Healthcare
Last Interim	June 30th, 2018	Industry	Biotechnology & Medical Research
Incorporated	October 7, 2003	Index	FTSE Aim All Share ,
Public Since	April 29, 2014	Exchange	London Stock Exchange (AIM)
Shares in Issue	5,140,674	Eligible for	an ISA? ☒ a SIPP? ☒
Free Float	4.31m (83.8%)		



Address 7 Romans Business Park East Street,
FARNHAM, GU9 7SX, United Kingdom

Web <http://www.bioventix.com/>

Phone +44 1252 728001

Contact ()

Auditors James Cowper Kreston

BVXPQuote

BVXP Share Price

GBP

2975p

Traded 4:22pm · Minimum 15 min delayed · NMS: 0.300k

Day's Change

▼ -75.0 -2.5%

Volume

5,720

Avg Vol (3m)

5,237

Bid - Ask

2,950.0 - 3,000.0

Open - Close

3,040.0 - 2,975.0

Low - High

0.0 - 0.0

12m Range

2,070.0 - 3,300.0


Spread

168bps

Beta

0.01

BVXP Share Price Performance



Latest BVXP News Announcements (delayed)

[More »](#)

- Mon 7:00am [Bioventix PLC: Results for the year ended 30 June 2018](#)
- 3rd Sep [Bioventix PLC: Notice of Results and Notice of AGM](#)
- 28th Aug [Bioventix PLC: Issue of Equity](#)
- 29th Jun [Bioventix PLC: Holding\(s\) in Company](#)
- 4th May [Bioventix PLC: Holding\(s\) in Company](#)

Upcoming BVXP Events

Thursday 25th October, 2018

Dividend For BVXP.L

Thursday 25th October, 2018

Dividend For BVXP.L

Thursday 6th December, 2018

Bioventix PLC Annual Shareholders Meeting

Recent ↓

Industry Peer Group

- Motif Bio**
[Compare vs BVXP](#)
- 4D Pharma**
[Compare vs BVXP](#)
- Tissue Regenix**
[Compare vs BVXP](#)
- Verona Pharma**
[Compare vs BVXP](#)
- Mainstay Medical I...**
[Compare vs BVXP](#)
- Oxford Biodynamics**
[Compare vs BVXP](#)
- Verseon**
[Compare vs BVXP](#)
- Creo Medical**
[Compare vs BVXP](#)

Healthcare

Biotechnology & Medical Research

Haynes Publishing

HYNS 200p 0.0 0.0%

Balanced, Micro Cap, Style Neutral

Market Cap

£30.2m

Quality

75

Enterprise Value

£27.7m

Value

60

Revenue

£33.8m

Momentum

40

Market Cap Rank

1352nd / 1923

StockRank™

63

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)

1m -0.6%

3m -12.9%

1yr -4.4%

Volume Change (%)

10d v 3m +16.9%

Price vs... (%)

52w High -19.3%

50d MA -4.73%

200d MA -9.67%

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) 11.8

PEG Ratio (f) 0.21

EPS Growth (f) 133.9 %

Dividend Yield (f) 3.75 %

Valuation (ttm)

Price to Book Value 1.21

Price to Tang. Book n/a

Price to Free Cashflow 25.4

Price to Sales 0.89

EV to EBITDA 2.81

Quality

vs. industry vs. market

Return on Capital 8.91 %


Return on Equity 6.45 %

Operating Margin 12.3 %

Health Trend

Piotroski F-Score

6



Bankruptcy Risk

Altman Z1-Score

1.84



Earnings Manipulation Risk

Low

Magic Formula Score

382 94% A+



Other Ratios

Leverage (ttm)	total	-intang	+pension
Gross Gearing	% 9.11		84.0
Net Gearing	% -10.1		64.7
Cash / Assets	% 8.13		11.9

Liquidity (ttm)	Efficiency (ttm)
Curr. Ratio 1.51	Asset Turnover 0.56
Quick Ratio 1.26	Rec's Turnover 4.43
Interest Cov. 90.5	Stock Turnover 3.87

Recent History

vs. industry vs. market

Latest interim period (ended 31st May '18) vs. prior year

Sales Growth 7.39 %

EPS Growth -21.0 %

3yr Compound Annual Growth Rate

Sales Growth 9.04 %

EPS Growth -62.3 %

DPS Growth n/a %

Margin of Safety (beta)

Broker Target	48%
Relative to Sector	31%
Stability Value (EPV)	-13%

Screens Passed


HYNS doesn't qualify for any screens.
Find out why: [View Checklists](#)

Financial Summary


Balance Sheet · Income Statement · Cashflow

Year End 31st May		2013	2014	2015	2016	2017	2018	2019E	2020E	CAGR / Avg
Revenue	£m	27.6	29.3	26.1	25.7	29.8	33.8	34.5	35.9	+4.1%
Operating Profit	£m	3.63	2.63	-6.72	-1.97	3.24	4.16			+2.8%
Net Profit	£m	2.15	1.12	-5.92	-1.78	1.37	1.49	2.50	2.80	-7.0%
EPS Reported	p	14.2	7.40	-39.2	-11.8	9.09	9.79			-7.2%
EPS Normalised	p	14.2	25.0	40.3	26.6	12.6	2.16	16.4	18.1	-31.3%
EPS Growth	%	-28.7	+76.5	+61.2	-34.1	-52.4	-82.9	+658.6	+10.4	
PE Ratio	x					92.5	12.2	12.2	11.0	
PEG	x					0.14	1.18	1.18	2.86	
Profitability										
Operating Margin	%	13.1	9.0	-25.8	-7.6	10.9	12.3			+2.0%
ROA	%		1.9	-10.7	-3.4	2.4	2.5			
ROCE	%	6.5	5.0	-15.2	-4.6	6.8	8.9			+1.2%
ROE	%		3.0	-19.2	-7.0	6.0	6.5			-2.1%
Cashflow										
Op. Cashflow ps	p	42.8	41.0	57.4	51.3	65.4	66.4			+9.2%
Capex ps	p	22.2	43.1	39.6	44.0	55.2	58.6			+21.5%
Free Cashflow ps	p	20.7	-2.12	17.9	7.31	10.2	7.81			-17.7%
Dividends										
Last ex-div: 25th Oct, paid: 15th Nov more...										
Dividend ps	p	7.50	7.50	7.50	7.50	7.50	7.50	7.50	7.50	
Dividend Growth	%	-52.2								
Dividend Yield	%					3.75	3.75	3.75	3.75	
Dividend Cover	x	1.89	0.99	-5.22	-1.57	1.21	1.31	2.19	2.41	
Balance Sheet										
Cash etc	£m	6.18	2.35	2.97	2.55	7.04	4.81			-4.9%
Working Capital	£m	13.9	10.0	7.90	4.58	6.77	6.28			-14.7%
Net Fixed Assets	£m	15.1	13.4	16.2	15.6	13.2	7.22			-13.7%
Net Debt	£m	-6.11	1.06	-0.14	-0.39	-3.71	-2.53			
Book Value	£m	39.1	35.3	26.5	24.2	21.3	25.0			-8.6%
Average Shares	m	15.1	15.1	15.1	15.1	15.1	15.3			+0.2%
Book Value ps	p	258.8	233.5	175.4	160.4	141.1	165.4			-8.6%

Graphical History Current Fiscal Year 2019



Broker Forecasts				31st May 2019			31st May 2020		
Price Target: 2.95 (+47.51% above Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				2.50m	16.4	7.50	2.80m	18.1	7.50
1m Change				-	-	-	-	-	-
3m Change				-	-	-	-	+0.20	-



Profile Summary



Haynes Publishing Group P.L.C. is a United Kingdom-based company, which creates and supplies practical and informative content to consumers and professional mechanics in print and digital formats. The Company operates through two geographical segments: UK & Europe, and North America & Australia. The UK & Europe segment has subsidiaries in the Netherlands and Italy, among others. Its core business is the publication and supply of automotive repair and technical information to the professional automotive and do it yourself (DIY) aftermarkets in both a print and digital format. The North America & Australia segment publishes DIY repair manuals for cars and motorcycles in both a print and digital format. It publishes titles under the Haynes, Chilton and Clymer brands, in both English and Spanish. It has a branch operation in Sydney, Australia, which publishes various products under both the Haynes and Gregory's brands. Its consumer content is delivered via both print and digital channels.

Directors: [Eddie Bell](#) (CHM) 65, [Jean Haynes](#) (CEO) 47, [Richard Barker](#) (FID), [James Bunkum](#) (COO), [Alex Kwarts](#) (CTO) 60, [Jeremy Yates-Round](#) (MDR) 53, [Peter Galien](#) (EDR), [John Haynes](#) (EDR) 76, [Stephen Daykin](#) (NED), [Nina Wright](#) (NED),

No. of Employees: 271

No. of Shareholders: n/a

Last Annual	May 31st, 2018
Last Interim	May 31st, 2018
Incorporated	May 18, 1960
Public Since	November 7, 1996
Shares in Issue	15,111,540
Free Float	3.60m (23.8%)

Sector [Consumer Cyclical](#)
Industry [Media & Publishing](#)
Index [FTSE Fledgling](#), [FTSE Fledgling Ex Investment Trusts](#),
Exchange [London Stock Exchange \(Full\)](#)
Eligible an ISA? ☒ a SIPP? ☒
for



Address [Chapel Cottage Sparkford Road, YEOVIL, BA22 7LG, United Kingdom](#)
Web <https://www.haynes.co.uk/investor/>
Phone +44 1963 440635
Contact ()
Auditors PricewaterhouseCoopers LLP

HYNSQuote				HYNS Share Price Performance			
HYNS Share Price	Day's Change	Volume	Bid - Ask	Low - High	Spread		
GBP	0.0 0.0%	858	196.0 - 204.0	0.0 - 0.0	400bps		
200p		Avg Vol (3m)	Open - Close	12m Range	Beta		
Traded 1:20pm · Minimum 15 min delayed · NMS: 0.500k		4,514	200.0 - 200.0	216.0 - 244.0	-0.11		

Latest HYNS News Announcements (delayed)		More »
24th Sep	Haynes Publishing - Annual Report and Notice of Annual General Meeting	
6th Sep	Haynes Publishing - Director/PDMR Shareholding	
5th Sep	BRIEF-Haynes Publishing FY Adj. Group Rev Rises 13.4 Pct	
5th Sep	Haynes Publishing - Preliminary Results	
26th Jul	Haynes Publishing - Director/PDMR Shareholding	

Upcoming HYNS Events
Thursday 25th October, 2018 Dividend For HYNS.L
Thursday 8th November, 2018 Haynes Publishing Group PLC Annual Shareholders Meeting
Thursday 24th January, 2019 (Estimate) Half Year 2019 Haynes Publishing Group PLC Earnings Release
Recent ↓

Industry Peer Group	
	Quarto Inc Compare vs HYNS
	Bonhill Compare vs HYNS
	Dods Compare vs HYNS
	Centaur Media Compare vs HYNS
	Connect Compare vs HYNS
	Independent News &... Compare vs HYNS
	Wilmington Compare vs HYNS
	Bloomsbury Publish... Compare vs HYNS
Consumer Cyclical	
Media & Publishing	

Supermarket Income REIT

SUPR 103p 0.0 0.0%Adventurous, Small Cap, **Momentum Trap**

Market Cap

£189.9m

Quality

13

Enterprise Value

£275.7m

Value

17

Revenue

£8.94m

Momentum


76

Market Cap Rank

850th / 1923

StockRank™

24

Zoom 1m 3m 6m YTD **1y** 2y 3y 5y All**Momentum**

Relative Strength (%)

1m +1.4%

3m +4.2%

1yr +5.9%

Volume Change (%)

10d v 3m +48.9%

Price vs... (%)

52w High -2.8%

50d MA +0.64%

200d MA +1.28%

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) 14.0

PEG Ratio (f) 0.21

EPS Growth (f) 216 %

Dividend Yield (f) 5.50 %

Valuation (ttm)

Price to Book Value 1.07

Price to Tang. Book 1.07

Price to Free Cashflow 23.6

Price to Sales 21.2

EV to EBITDA 40.3

Margin of Safety (beta)

Broker Target

9%

Relative to Sector

-33%

Graham Formula

23%

Screens Passed 1

SUPR qualifies for **52 Week High Momentum Screen** (in Momentum)

[View Screen](#) · [View Checklist](#)

Quality

vs. industry vs. market

Return on Capital 1.04 %

Return on Equity 0.70 %

Operating Margin 30.9 %


Financial Summary

Balance Sheet · Income Statement · Cashflow

Year End 30th Jun		2013	2014	2015	2016	2017	2018	2019E	2020E	CAGR / Avg
Revenue	£m	0.000	0.000	0.000	0.000	0.000	8.94	16.2	17.2	
Operating Profit	£m	0.000	0.000	0.000	0.000	0.000	2.76			
Net Profit	£m	0.000	0.000	0.000	0.000	0.000	0.62	19.9	23.8	
EPS Reported	p	0.000	0.000	0.000	0.000	0.000	0.50			
EPS Normalised	p	0.000	0.000	0.000	0.000	0.000	0.50	7.10	8.00	
EPS Growth	%							+1,323	+12.7	
PE Ratio	x						206.4	14.5	12.9	
PEG	x						0.16	1.14	1.14	
Profitability										
Operating Margin	%						30.9			+30.9%
ROA	%									
ROCE	%						1.0			+1.0%
ROE	%						0.7			+0.7%
Cashflow										
Op. Cashflow ps	p	0.000	0.000	0.000	0.000	0.000	6.49			
Capex ps	p	0.000	0.000	0.000	0.000	0.000	0.000			
Free Cashflow ps	p	0.000	0.000	0.000	0.000	0.000	6.49			
Dividends										
Last ex-div: 18th Oct, paid: 6th Nov more...										
Dividend ps	p						1.10	5.60	5.82	
Dividend Growth	%							+409.1	+3.87	
Dividend Yield	%						1.07	5.44	5.65	
Dividend Cover	x						0.45	1.27	1.38	
Balance Sheet										
Cash etc	£m	0.000	0.000	0.000	0.000	0.000	2.24			
Working Capital	£m	n/a	n/a	n/a	n/a	n/a	-0.092			
Net Fixed Assets	£m	0.000	0.000	0.000	0.000	0.000	264.9			
Net Debt	£m	0.000	0.000	0.000	0.000	0.000	85.9			
Book Value	£m	0.000	0.000	0.000	0.000	0.000	176.7			
Average Shares	m	0.000	0.000	0.000	0.000	0.000	124.2			
Book Value ps	p	0.000	0.000	0.000	0.000	0.000	95.9			

Health Trend [Piotroski F-Score](#)

3

**Bankruptcy Risk** [Altman Z2-Score](#)

2.56

**Earnings Manipulation Risk**

N/A

Magic Formula Score

1821 38% D+

**Other Ratios**

Leverage (ttm)		total	-intang	+pension
Gross Gearing	%	49.8	49.8	49.8
Net Gearing	%	48.6	48.6	48.6
Cash / Assets	%	0.83		0.83

Liquidity (ttm)		Efficiency (ttm)	
Curr. Ratio	0.97	Asset Turnover	0.037
Quick Ratio	0.97	Rec's Turnover	n/a
Interest Cov.	1.85	Stock Turnover	n/a

Recent History


vs. industry vs. market

Latest interim period (ended 30th Jun '18) vs. prior year


Sales Growth	n/a	%		
EPS Growth	n/a	%		

3yr Compound Annual Growth Rate

Sales Growth	n/a	%		
EPS Growth	n/a	%		
DPS Growth	n/a	%		

Graphical History Current Fiscal Year 2019

Broker Forecasts			30th Jun 2019			30th Jun 2020		
Price Target: 1.13 (+9.21% above Price)			Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a			(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate			19.9m	7.10	5.60	23.8m	8.00	5.82
1m Change			-1.05m	-2.10	-0.050	+100.0k	-1.60	-0.083
3m Change			+500k	+0.90	-0.10	+100.0k	+1.70	-0.083



Profile Summary



Supermarket Income REIT plc is a United Kingdom-based, closed-ended investment company. The Company intends to carry on business as a real estate investment trust (REIT). The Company's investment objective is to provide its shareholders with an income together with capital growth by investing in a diversified portfolio of supermarket real estate assets in the United Kingdom. The Company is focused on investing in a diversified portfolio of principally freehold and long leasehold operational properties. The Company may invest, directly or indirectly, at least 80% of its gross asset value in properties let to the United Kingdom supermarket operators and it may invest up to 20% of its gross asset value in asset let to non-supermarket operators. Atrato Capital Limited is the investment advisor of the Company. The Company is not engaged in any operations.

No Management Information.

No. of Employees: n/a

No. of Shareholders: n/a

Last Annual	June 30th, 2018	Sector	Financials
Last Interim	June 30th, 2018	Industry	Residential & Commercial REITs
Incorporated	June 1, 2017	Index	
Public Since	July 21, 2017	Exchange	London Stock Exchange (Full)
Shares in Issue	184,356,434	Eligible for	an ISA? ☒ a SIPP? ☒
Free Float	175.7m (95.3%)		



Address 8 Greencoat Place, LONDON, SW1P 1PL, United Kingdom
Web <https://www.supermarketincomereit.co>
Phone +44 20 37908087
Auditors BDO LLP

SUPRQuote


SUPR Share Price Day's Change
 GBp 0.0 0.0%

103p

Traded 3:22pm · Minimum 15 min delayed · NMS: 3.00k

Volume	Bid - Ask	Low - High	Spread
377,027	102.0 - 104.0	0.0 - 0.0	194bps
Avg Vol (3m)	Open - Close	12m Range	Beta
185,098	103.0 - 103.0	104.0 - 106.0	0.00

SUPR Share Price Performance



Latest SUPR News Announcements (delayed)

[More »](#)

Mon 8:00am	Supermarket Inc REIT - Dividend Declaration
2nd Oct	Supermarket Inc REIT - Director/PDMR Shareholding
27th Sep	Supermarket Inc REIT - PDMR Shareholding
27th Sep	Supermarket Inc REIT - Notice of AGM
11th Sep	Supermarket Inc REIT - PDMR Shareholding - Replacement

Upcoming SUPR Events

Thursday 18th October, 2018

Dividend For SUPR.L

Tuesday 6th November, 2018

Supermarket Income REIT PLC Annual Shareholders Meeting

Recent ↓

Industry Peer Group	
	Newriver Reit Compare vs SUPR
	Hibernia REIT Compare vs SUPR
	Green REIT Compare vs SUPR
	UK Commercial Prop... Compare vs SUPR
	Londonmetric Prope... Compare vs SUPR
	Workspace Compare vs SUPR
	Great Portland Est... Compare vs SUPR
	Intu Properties Compare vs SUPR

[Financials](#)

[Residential & Commercial REITs](#)

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2018.